WebMD explains different types of childhood leukemia, including risk factors, diagnosis, symptoms, and treatment.
Childhood Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - nci_ncicdr0000062707-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Adult Non-Hodgkin Lymphoma Treatment
Childhood Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - To Learn More About Childhood Non-Hodgkin Lymphoma
For more information from the National Cancer Institute about childhood non-Hodgkin lymphoma, see the following:What You Need to Know About™ Non-Hodgkin LymphomaComputed Tomography (CT) Scans and CancerDrugs Approved for Non-Hodgkin LymphomaBone Marrow Transplantation and Peripheral Blood Stem Cell TransplantationTargeted Cancer TherapiesUnderstanding Cancer Series: Targeted Therapies (Advances in Targeted Therapies and Targeted Therapies for Lymphoma)Understanding Cancer Series: The Immune SystemFor more childhood cancer information and other general cancer resources, see the following:What You Need to Know About™ CancerChildhood CancersCureSearch for Children's CancerLate Effects of Treatment for Childhood CancerAdolescents and Young Adults with CancerYoung People with Cancer: A Handbook for ParentsCare for Children and Adolescents with CancerUnderstanding Cancer Series: CancerCancer StagingCoping with Cancer: Supportive and Palliative CareQuestions to Ask Your Doctor About
Important It is possible that the main title of the report Granulomatosis, Lymphomatoid is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report. ...
Childhood Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Late Effects of Treatment for Adult NHL
Late effects of treatment for non-Hodgkin lymphoma (NHL) have been observed. Pelvic radiation therapy and large cumulative doses of cyclophosphamide have been associated with a high risk of permanent sterility. For as many as three decades after diagnosis, patients are at a significantly elevated risk for second primary cancers, especially the following:[1,2,3]Lung cancer.Brain cancer.Kidney cancer.Bladder cancer.Melanoma.Hodgkin lymphoma.Acute nonlymphocytic leukemia.Left ventricular dysfunction was a significant late effect in long-term survivors of high-grade NHL who received more than 200 mg/m² of doxorubicin.[4,5]Myelodysplastic syndrome and acute myelogenous leukemia are late complications of myeloablative therapy with autologous bone marrow or peripheral blood stem cell support, as well as conventional chemotherapy-containing alkylating agents.[1,6,7,8,9,10,11,12,13] Most of these patients show clonal hematopoiesis even before the transplantation, suggesting that the
Childhood Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment for Indolent, Noncontiguous Stage II / III / IV Adult NHL
Optimal treatment of advanced stages of low-grade non-Hodgkin lymphoma (NHL) is controversial because of low cure rates with the current therapeutic options. Numerous clinical trials are in progress to settle treatment issues, and patients should be urged to participate. The rate of relapse is fairly constant over time, even in patients who have achieved complete response to treatment. Indeed, relapse may occur many years after treatment. Currently, no randomized trials guide clinicians about the initial choice of watchful waiting, rituximab, nucleoside analogs, alkylating agents, combination chemotherapy, radiolabeled monoclonal antibodies, or combinations of these options.; [Level of evidence: 1iiDiii]For patients with indolent, noncontiguous stage II and stage III non-Hodgkin lymphoma, central lymphatic radiation therapy has been proposed but is not usually recommended as a form of treatment.[3,4]Numerous prospective clinical trials of
Primary Gastric Lymphoma
Non-Hodgkins Type Gastric Lymphoma is a rare form of stomach cancer characterized by unrestrained growth of certain lymphoid cells of the stomach. This form of cancer is thought to arise from certain white blood cells (lymphocytes) within lymphoid tissue of the stomach's mucous membrane (mucosa). Non-Hodgkins Type Gastric Lymphoma may be a primary disease process (primary lymphoma) or may ...
Childhood Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Options for Chronic Myeloproliferative Neoplasms
A link to a list of current clinical trials is included for each treatment section. For some types or stages of cancer, there may not be any trials listed. Check with your doctor for clinical trials that are not listed here but may be right for you.Chronic Myelogenous LeukemiaSee the PDQ summary about Chronic Myelogenous Leukemia Treatment for information.Polycythemia VeraThe purpose of treatment for polycythemia vera is to reduce the number of extra blood cells. Treatment of polycythemia vera may include the following: Phlebotomy.Chemotherapy with or without phlebotomy.Biologic therapy using interferon alfa or pegylated interferon alpha..Low-dose aspirin.Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with polycythemia vera. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is
Childhood Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Option Overview
Many of the improvements in childhood cancer survival have been made using combinations of known and/or new agents that have attempted to improve the best available, accepted therapy. Clinical trials in pediatrics are designed to compare potentially better therapy with therapy that is currently accepted as standard. This comparison may be done in a randomized study of two treatment arms or by evaluating a single new treatment and comparing the results with those previously obtained with standard therapy. All children with non-Hodgkin lymphoma (NHL) should be considered for entry into a clinical trial. Treatment planning by a multidisciplinary team of cancer specialists with experience treating tumors of childhood is strongly recommended to determine, coordinate, and implement treatment to achieve optimal survival. Children with NHL should be referred for treatment by a multidisciplinary team of pediatric oncologists at an institution with experience in treating pediatric cancers.
Mantle Cell Lymphoma
Important It is possible that the main title of the report Mantle Cell Lymphoma is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report. ...